Genomic cancer testing aids in examining DNA and RNA samples for mutations that may indicate the risk of cancer, its stage or progression. It helps in developing personalized treatment plans by providing information about cancer susceptibility, prognosis and selecting targeted therapies. With the rising prevalence of cancer globally, genomic cancer testing plays an important role in early detection and diagnosis. The growing demand for non-invasive tests and precision medicine is driving more individuals to undergo genomic cancer screening.

The global genomic cancer testing market was valued at US$ 13 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The opportunity in early cancer detection and treatment presents lucrative prospects for the genomic cancer testing market. Genomic testing aids in detecting cancer at an early stage, even before the onset of symptoms, allowing clinicians to administer timely intervention. Early diagnosis improves survival rates and lowers healthcare costs associated with advanced cancer treatment. With increasing awareness about the importance of screening, more individuals are opting for genomic tests that can detect multiple cancer types with high accuracy. Rising government initiatives promoting screening programs also point towards the growing adoption of genomic testing for catching cancer early. The market stands to gain significantly from its ability to enable early detection and management of cancer.

Porter's Analysis

Threat of new entrants: The threat of new entrants is moderate as genomic cancer testing requires high infrastructure and research costs. However, opportunities exist for new players to enter regional markets or develop new testing technologies.

Bargaining power of buyers: The bargaining power of buyers is high as Global genomic cancer testing market size is not an essential service and buyers have many options to choose from. However, personalized therapy options increase customer retention for major providers.

Bargaining power of suppliers: The bargaining power of suppliers is moderate since they are dependent on few pharma and diagnostic players. However, the industry is innovating rapidly which increases suppliers' importance.

Threat of new substitutes: The threat of substitutes is moderate as new diagnostic methods can replace genomic tests. However, increasing focus on precision medicine makes it difficult to find an outright substitute.

Competitive rivalry: The competitive rivalry is high due to the presence of many global and regional players offering similar testing services. Players compete on service portfolio, geographic reach, and pricing.

Get More Insights On This Topic: https://medicalinfoblogs.weebly.com/blog/genomic-cancer-testing-market-is-estimated-to-witness-high-growth-owing-to-opportunity-in-early-cancer-detection-and-treatment